NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 125,000 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 125,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the transaction, the insider owned 69,302 shares of the company’s stock, valued at approximately $1,864,916.82. This trade represents a 64.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

NewAmsterdam Pharma Stock Up 1.8%

NewAmsterdam Pharma stock traded up $0.49 during mid-day trading on Tuesday, hitting $27.34. The company’s stock had a trading volume of 1,986,350 shares, compared to its average volume of 1,043,099. The stock has a market capitalization of $3.27 billion, a P/E ratio of -12.66 and a beta of 0.10. The stock’s fifty day moving average price is $30.58 and its two-hundred day moving average price is $32.11. NewAmsterdam Pharma Company N.V. has a twelve month low of $23.05 and a twelve month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. Equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC raised its stake in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the last quarter. KBC Group NV acquired a new position in shares of NewAmsterdam Pharma during the first quarter valued at about $37,000. Navalign LLC bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $46,000. Finally, AdvisorNet Financial Inc acquired a new stake in NewAmsterdam Pharma during the first quarter worth about $82,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price on the stock. Finally, Royal Bank Of Canada dropped their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $49.73.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.